Jan 052017
 

By Talent4Boards Team

Talent4Boards - Great Talent builds Great Boards

– UK, Stevenage – NeRRe Therapeutics, a clinical-stage company developing a unique portfolio of neurokinin receptor antagonists for the treatment of common, chronic and debilitating conditions caused by neuronal hypersensitivity, announced it has raised £23 million in an oversubscribed Series B financing round.… => Read more

NeRRe Therapeutics strengthens its Board along with raising £23m Series B financing

From:: NeRRe Therapeutics strengthens its Board along with raising £23m Series B financing

Sorry, the comment form is closed at this time.

%d bloggers like this: